Asgard Therapeutics
Last verified 2026-05-06. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $32.4Mattributed |
|---|---|
| Latest round | series-a, $32.4M, 2024-03-01attributed |
| Founded | 2018 |
| Headquarters | Lund |
| Industry | bio |
| Stage | series-a |
| Website | asgardtx.com |
Asgard Therapeutics is a Swedish biotech developing direct cell reprogramming gene therapies, with lead candidate AT-108 turning tumor cells into antigen-presenting dendritic cells. The off-the-shelf therapy targets patients with solid tumors needing personalized anti-tumor immune responses. Science-published proof-of-concept data shows.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-03-01 | series-a | $32.4M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $32.4M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $32.4M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | asgardtx.com, read 2026-05-06 |
| Description | self-reported | asgardtx.com, read 2026-05-06 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.